CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-26

Study Completion Date

2019-04-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open-label multicenter study using CGB-400 Gel to reduce facial redness, bumps, and blemishes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CGB-400 for the Reduction of Facial Redness

NCT04508660

Rosacea

COMPLETED PHASE1

CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

NCT04886739

Rosacea

COMPLETED PHASE2

Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions

NCT04539886

Skin Lesion Skin Abnormalities Sebaceous Hyperplasia

COMPLETED NA

A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

NCT03564119

Papulopustular Rosacea

COMPLETED PHASE3

Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

NCT01796795

Common Wart

SUSPENDED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Open-label multicenter study to evaluate the ability of CGB-400 Gel to reduce facial redness and bumps/blemishes typically associated with rosacea. Approximately 25 subjects will be enrolled.

Subjects will receive study treatment for 12 weeks and attend a total of 5 study visits (i.e., BL, W2, W4, W8, W12).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rosacea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects with redness and bumps and/or blemishes

Topical administration twice daily for 12 weeks

Group Type EXPERIMENTAL

CGB-400

Intervention Type DRUG

BID application

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CGB-400

BID application

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Outpatient, male or female of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative UPT at Baseline and practice a reliable method of contraception throughout the study.
2. Facial redness associated with rosacea with or without bumps or blemishes.
3. Facial redness (IGA-R) score of 2 or 3 (i.e., mild or moderate).
4. IGA score of 2 or 3 (i.e., mild or moderate).
5. Absence of any skin conditions that could interfere with the visual erythema assessments.
6. Willing to forego any other topical or non-topical treatment on the study areas during treatment (other than sun protection or the study specified face wash and moisturizer).
7. Willing to use the provided skincare regimen (e.g., face wash and moisturizer) over the duration of the study.
8. Sign the IRB-approved ICF (which includes HIPAA) prior to any study-related procedures being performed.

Exclusion Criteria

1. Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Products (i.e., essential oils, fragrance, choline, phosphatidylcholine, etc.).
2. Any transient flushing syndrome.
3. History of basal cell carcinoma within 6 months of Visit 1.
4. History or presence of a skin condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.).
5. Diagnosis of severe rosacea, ocular rosacea, rhinophymatous rosacea, or acne fulminans at Baseline.
6. Blepharitis/meibomianitis requiring systemic treatment by an ophthalmologist.
7. Uncontrolled systemic disease.
8. Foreseen unprotected and intense/excessive UV exposure during the course of the study.
9. Use of any of the following concomitant medications/procedures:

* Cosmetic and/or OTC products for redness reduction and/or skin clearing
* Topical medications for rosacea
* Systemic antibiotics or corticosteroids
* Topical antibiotics, corticosteroids, or antiparasitic agents
* Intense/excessive ultraviolet (UV) radiation
* Phototherapy, energy-based therapy, facials, chemical peels, microdermabrasion
10. Exposure to any other investigational drug/device within 30 days prior to study entry.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No